


Amendments To The Claims


1-6. (canceled)

7. (currently amended) A compound selected from the following formulae (C1) to (C11) and (C13)-(C20) or a pharmaceutically acceptable salt or prodrug derivative thereof:


C1)




C2)




C3)




C4)




C5)




C6)




C7)




C8)




C9)




C10)




C11)




C13)




C14)




C-15)




C16)




C17)




C18)




C19)



C20)








8. (currently amended) A compound represented by the structural formula AA







or a pharmaceutically acceptable salt or prodrug thereof.

9. (currently amended) A compound selected from the group consisting of:







or a pharmaceutically acceptable salt or prodrug derivative thereof.

10. (canceled)

11. (currently amended) ~~An ester derivative of the A compound according to of~~
~~claim 36 wherein Z_{EP} includes a carboxyl group functionalized as a selected from a methyl ester;~~
~~ethyl ester; N,N-diethylglycolamido ester;~~ or morpholinylethyl ester.

12. (previously presented) The salt derivative of the compound of claim 36 wherein the salt is sodium or potassium.

13. (previously presented) A pharmaceutical formulation comprising the compound of claim 36 either with a pharmaceutically acceptable carrier or diluent.

14. (withdrawn) A formulation for treating osteoporosis comprising:

Ingredient (A1): the vitamin D receptor modulator of claim 36 or;

Ingredient (B1):

one or more co-agents selected from the group consisting of:

- a. estrogens,
- b. androgens,
- c. calcium supplements,
- d. vitamin D metabolites,
- e. thiazide diuretics,
- f. calcitonin,
- g. bisphosphonates,
- h. SERMS, and
- i. fluorides; and

Ingredient (C1): optionally, a carrier or diluent.

15. (withdrawn) The formulation of claim 14 wherein the weight ratio of (A1) to (B1) is from 10:1 to 1:1000.

16. (withdrawn) A formulation for treating psoriasis comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 36;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

- a. topical glucocorticoids ,
- b. salicylic acid,
- c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

17. (withdrawn) The formulation of claim 16 wherein the weight ratio of (A2) to (B2) is from 1:10 to 1:100000.

18. (withdrawn) A method of treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Insufficient sebum secretion, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, Psoriasis, Scleroderma, Skin cancer, Skin cell damage from, Mustard vesicants, Wrinkles or Seborrheic dermatitis; wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to claim 36.

19. (withdrawn) The method of claim 18 for the treatment of psoriasis.


20. (withdrawn) The method of claim 18 for the treatment of osteoporosis.

21-22. (canceled)

23. (withdrawn, currently amended) A method of treating ~~or preventing~~ disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound according to claim 36.

24-35. (canceled)

36. (currently amended) A compound represented by a formula below:




wherein

R and R' are independently C₁-C₅ alkyl, ~~C₁-C₅ fluoroalkyl~~, or together R and R' form a ~~substituted or unsubstituted, saturated or unsaturated~~ carbocyclic ring having from 3 to 8 carbon atoms;

~~RP₃ is selected from hydrogen, halo, or C₁-C₅ alkyl; C₁-C₅ fluoroalkyl; O-C₁-C₅ alkyl; S-C₁-C₅ alkyl; O-C₁-C₅ fluoroalkyl; CN; NO₂; acetyl; S-C₁-C₅ fluoroalkyl; C₂-C₅ alkenyl; C₃-C₅ cycloalkyl; or C₃-C₅ cycloalkenyl;~~

~~(Lp₂) is a divalent linking group independently selected from:~~



~~where m is 0, 1, or 2, and each R40 is independently hydrogen, C₁-C₅ alkyl, or C₁-C₅ fluoroalkyl;~~

Z_P is a

branched C₃-C₅ alkyl;

~~1-hydroxycyclopentenyl;~~



















~~1-hydroxycyclohexenyl;~~

~~1-hydroxycycloheptyl;~~
~~1-hydroxycyclooctenyl;~~
~~1-hydroxycyclopropyl;~~
~~1-hydroxycyclobutyl;~~
~~1-hydroxycyclopentyl;~~
~~1-hydroxycyclohexyl;~~
~~2-oxocyclohexyloxy~~
~~2-oxocyclohexylmethyl~~
~~3-methyl-2-oxocyclohexyloxy~~
~~3-methyl-2-oxocyclohexylmethyl~~
~~3,3-dimethyl-2-oxocyclohexyloxy~~
~~3,3-dimethyl-2-oxocyclohexylmethyl~~
~~2-hydroxycyclohexyloxy~~
~~2-hydroxycyclohexylmethyl~~
~~3-methyl-2-hydroxycyclohexyloxy~~
~~3-methyl-2-hydroxycyclohexylmethyl~~
~~3,3-dimethyl-2-hydroxycyclohexyloxy~~
~~3,3-dimethyl-2-hydroxycyclohexylmethyl~~
~~1-hydroxycycloheptyl; or~~
~~1-hydroxycyclooctyl;~~

Z_{FB} is attached to the 5 or 6 position on the benzofuranyl ring and selected from:

~~-CO₂H~~
~~-CO₂(C₁-C₅ alkyl),~~
~~-C(O)NMe₂~~
~~-CO₂(C₂-C₅ alkenyl);~~
~~-CO₂(C₃-C₅ cycloalkyl);~~
~~-CO₂(C₃-C₅ cycloalkenyl);~~
~~-CO₂(C₄-C₅ hydroxyalkyl);~~
~~-CO₂(C₄-C₅ fluoroalkyl);~~
~~-CO₂(C₄-C₅ alkyl)-phenyl;~~
~~-CO₂(C₄-C₅ alkyl)-(O)-(C₄-C₅ alkyl);~~
~~-CO₂(C₁-C₅ alkyl)-NH₂,~~

~~CO₂(C₄-C₅-alkyl)-NH-(C₄-C₅-alkyl)₂;~~
~~CO₂(C₄-C₅-alkyl)-C(O)-NH₂;~~
~~CO₂(C₄-C₅-alkyl)-C(O)-NH-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-C(O)-N-(C₄-C₅-alkyl)₂;~~
~~CO₂(C₄-C₅-alkyl)-C(O)-OH;~~
~~CO₂(C₄-C₅-alkyl)-C(O)-NH-5-tetrazolyl;~~
~~CO₂(C₄-C₅-alkyl)-C(O)-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-C(O)-(O-C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-NH₂;~~
~~CO₂(C₄-C₅-alkyl)-NH-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-N-(C₄-C₅-alkyl)₂;~~
~~CO₂(C₄-C₅-alkyl)-NH-SO₂-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-N-pyrrolidin-2-one;~~
~~CO₂(C₄-C₅-alkyl)-N-pyrrolidine;~~
~~CO₂(C₄-C₅-alkyl)-(1-methylpyrrolidin-2-one-3-yl);~~
~~CO₂(C₄-C₅-alkyl)-SO₂-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-SO₂-NH₂;~~
~~CO₂(C₄-C₅-alkyl)-SO₂-NH-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-SO₂-N-(C₄-C₅-alkyl)₂;~~
~~CO₂(C₄-C₅-alkyl)-SO₂-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-S(O)-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-S(O)-NH₂;~~
~~CO₂(C₄-C₅-alkyl)-S(O)-NH-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-S(O)-N-(C₄-C₅-alkyl)₂;~~
~~CO₂(C₄-C₅-alkyl)-S(O)-(C₄-C₅-alkyl);~~
~~CO₂(C₄-C₅-alkyl)-P(O)-(O-C₄-C₅-alkyl)₂;~~
~~CO₂(C₄-C₅-alkyl)-5-tetrazolyl;~~
~~CO₂CH₂-CO₂H;~~
~~CO₂CH₂-5-tetrazolyl;~~




~~-C(O)NH-CH(CF₃)-C(O)OH;~~
~~-C(O)NH-CH(OH)-C(O)OH;~~
~~-C(O)NH-CH(cyclopropyl)-C(O)OH;~~
~~-C(O)NH-C(Me)₂-C(O)OH;~~
~~-C(O)NH-C(Me)₂-C(O)OH;~~
~~-C(O)NH-CF(Me)-C(O)OH;~~
~~-C(O)NH-C(Me)(CF₃)-C(O)OH;~~
~~-C(O)NH-C(Me)(OH)-C(O)OH;~~
~~-C(O)NH-C(Me)(cyclopropyl)CO₂H~~
 -C(O)NMe-CH₂-C(O)OH,
 -C(O)NMe-CH₂-C(O)OMe,
 -C(O)NMe-CH₂-C(O)OEt,
 -C(O)NMe-CH₂-C(O)OiPr,
 -C(O)NMe-CH₂-C(O)tBu,
~~-C(O)NMe-CH₂-C(O)OH;~~
 -C(O)NMe-CH(Me)-C(O)OH,
~~-C(O)NMe-CH(F)-C(O)OH;~~
~~-C(O)NMe-CH(CF₃)-C(O)OH;~~
~~-C(O)NMe-CH(OH)-C(O)OH;~~
~~-C(O)NMe-CH(cyclopropyl)-C(O)OH;~~
~~-C(O)NMe-C(Me)₂-C(O)OH;~~
~~-C(O)NMe-CF(Me)-C(O)OH;~~
~~-C(O)NMe-C(Me)(CF₃)-C(O)OH;~~
~~-C(O)NMe-C(Me)(OH)-C(O)OH;~~
~~-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH;~~
~~-C(O)NHS(O)Me;~~
~~-C(O)NHSO₂Me;~~
 -C(O)-NH-5-tetrazolyl,
-O-SO₂-C₁-C₅ alkyl),
-SO₂(C₁-C₅ alkyl),
CH₂S(O)₂Me,
CH₂S(O)₂Et, and
CH₂S(O)₂iPr,

~~-C(O)NHS(O)Me;~~
~~-C(O)NHS(O)Et;~~
~~-C(O)NH₂SO₂Me;~~
~~-C(O)NH₂SO₂Et;~~
~~-C(O)NHS(O)iPr;~~
~~-C(O)NH₂SO₂iPr;~~
~~-C(O)NHS(O)tBu;~~
~~-C(O)NH₂SO₂tBu;~~
~~-C(O)NHCH₂S(O)Me;~~
~~-C(O)NHCH₂S(O)Et;~~
~~-C(O)NHCH₂SO₂Me;~~
~~-C(O)NHCH₂SO₂Et;~~
~~-C(O)NHCH₂CH₂S(O)Me;~~
~~-C(O)NHCH₂CH₂S(O)Et;~~
~~-C(O)NHCH₂CH₂SO₂Me;~~
~~-C(O)NHCH₂CH₂SO₂Et;~~
~~-C(O)N(Me)S(O)Me;~~
~~-C(O)N(Me)SO₂Me;~~
~~-C(O)N(Me)-5-tetrazolyl;~~
~~-C(O)N(Me)S(O)Me;~~
~~-C(O)N(Me)S(O)Et;~~
~~-C(O)N(Me)SO₂Me;~~
~~-C(O)N(Me)SO₂Et;~~
~~-C(O)N(Me)S(O)iPr;~~
~~-C(O)N(Me)SO₂iPr;~~
~~-C(O)N(Me)S(O)tBu;~~
~~-C(O)N(Me)SO₂tBu;~~
~~-C(O)N(Me)CH₂S(O)Me;~~
~~-C(O)N(Me)CH₂S(O)Et;~~
~~-C(O)N(Me)CH₂SO₂Me;~~

~~$\text{--C(O)N(Me)CH}_2\text{SO}_2\text{Et}$,
 $\text{--C(O)N(Me)CH}_2\text{CH}_2\text{S(O)Me}$,
 $\text{--C(O)N(Me)CH}_2\text{CH}_2\text{S(O)Et}$,
 $\text{--C(O)N(Me)CH}_2\text{CH}_2\text{SO}_2\text{Me}$, and
 $\text{--C(O)N(Me)CH}_2\text{CH}_2\text{SO}_2\text{Et}$~~


and a pharmaceutically acceptable salt or prodrug thereof.

37. (previously presented) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.


38. (previously presented) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

39. (withdrawn) A method of treating a mammal or alleviating the pathological effects of psoriasis, scleroderma, seborrheic dermatitis or skin cancer or, a mammal in need thereof comprising administered a pharmaceutically effective amount of a compound of Claim 37, or a pharmaceutically acceptable salt thereof.

40 (new) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

41. (new) A pharmaceutical formulation comprising the compound of claim 37 with a pharmaceutically acceptable carrier or diluent.

42. (new) A pharmaceutical formulation comprising the compound of claim 38 with a pharmaceutically acceptable carrier or diluent.

43. (new) A pharmaceutical formulation comprising the compound of claim 40 with a pharmaceutically acceptable carrier or diluent.